

Group
~~1643~~

RECEIVED
JUL 1 2002
TRANSFES
TECH CENTER
600/2900

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Date Considered

USCOMM-DC 80-398.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P5009R1Serial No.
09/938,418

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

23 Aug 2001

Group

1645

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
<i>AS</i>	9	5,871,969	16.02.99	Hastings et al.			12.02.97
<i>AS</i>	10	6,287,777	09.09.01	Sytowski et al.			10.08.99

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
<i>AS</i>	11	1130094A2	05.09.01	EP				
	12	00/37638	29.06.00	WO				
	13	00/53756	14.09.00	WO				
	14	97/29189	14.08.97	WO				
	15	98/45442	15.10.98	WO				
	16	98/50073	12.11.98	WO				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

<i>AS</i>	17	Campo, Cathrin A. et al., "Zinc Inhibits the Mixed Lymphocyte Culture" <u>Biological Trace Element Research</u> , Humana Press, Inc. Vol. 79(1):15-22 (2001)
	18	"Database Search, DNA sequence alignments [BLASTN 2.1.3 (April-1-2001). NCBI] A1-A23"
	19	"Database Search, protein sequence alignments [BLASTP 2.2.1 (July-12-2001). NCBI] B1-B9"
	20	Feinstein, Yael et al., "F-spondin and mindin: two structurally and functionally related genes expressed in the hippocampus that promote outgrowth of embryonic hippocampal neurons" (Development 126), Great Britain: The Company of Biologists Limited pps. 3637-3648 (1999)
	21	Feinstein, Yael et al., "The neuronal class 2 TSR proteins F-spondin and Mindin: a small family with divergent biological activities" <u>The International Journal of Biochemistry and Cell Biology</u> 36:975-980 (2004)
	22	Higashijima et al. <u>Dev. Biol.</u> pps. 192:211-227 (1997)
	23	Johnson et al., "Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials" <u>British Journal of Cancer</u> 84(10):1424-1431 (2001)
	24	Kahan, "Immunosuppressive therapy" <u>Current Opinion in Immunology</u> 4(5):553-560 (Oct 1992)
	25	Klar et al. <u>Cell</u> pps. 69:95-110 (1992)
	26	Manda, et al., "Identification of Genes (SPON2 and C20orf2) Differentially Expressed between Cancerous and Noncancerous Lung Cells by mRNA Display" <u>Genomics</u> 61(1):5-14 (1999)
	27	Piccotti, Joseph R. et al., "Interleukin-12 (IL-12)-Driven Alloimmune Responses In Vitro and In Vivo" <u>Transplantation</u> 67(No. 11):1453-1460 (Jun 15, 1999)
	28	Reinsmoen, Nancy L et al., "Evaluation of the Cellular Immune Response in Transplantation" <u>Manual of Clinical Laboratory Immunology</u> , Noel R. Rose; Robert G. Hamilton; and Barbara Dettr, Sixth edition, Washington, D.C.: ASM Press pps. 1164-1166 (2002)
	29	"Sequence Alignment of SEQ ID NO: 235 of USSN 10/145,128 with AAV63241 of Sheppard (W098/45442)"

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P5009R1

Serial No.

09/938,418

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

23 Aug 2001

Group

1645

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

30 "Sequence Alignment of Sytkowski et al. (U.S. Patent No. 6287777), Wood et al. (WO 99/46281), Ashkenazi et al. (WO 00/37638), Hastings et al. (U.S. Patent No. 5871969 and WO 9829189), Ali et al. (WO 00/23108) and Jonak et al. (WO 98/50073)"

31 Shi, Leming M. et al., "Mining and Visualizing Large Anticancer Drug Discovery Databases" J. Chem. Inf. Comput. Sci. 40:367-379 (2000)


32 Stites, Daniel P. et al., "Basic and Clinical Immunology" Basic and Clinical Immunology (8th Edition), Paramount Publishing Business and Professional Group, pps. 30-31, 208-209, 246-247 (1994)

33 Umemiya et al. Dev. Biol. pps. 186:165-176 (1997)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P5009R1

Serial No.

09/938,418

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

23 Aug 2001

Group

1645

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

7

"BLAST Results A-1 - A-531"

8

"BLAST Results B-1 - B-194"

*References
Not
Submitted***RECEIVED**

SEP 25 2003

TECH CENTER 1600/2900

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.